Medical device company DexCom (NASDAQ:DXCM) will be reporting earnings this Thursday after market close. Here’s what investors should know.
DexCom beat analysts’ revenue expectations last quarter, reporting revenues of $1.26 billion, up 13.1% year on year. It was a mixed quarter for the company, with a beat of analysts’ EPS estimates but full-year revenue guidance meeting analysts’ expectations.
Is DexCom a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting DexCom’s revenue to grow 13.5% year on year, in line with the 12.5% increase it recorded in the same quarter last year.
Heading into earnings, analysts covering the company have grown increasingly bullish with revenue estimates seeing in majority upward revisions over the last 30 days. DexCom rarely misses Wall Street’s revenue estimates.
Looking at DexCom’s peers in the healthcare equipment and supplies segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Intuitive Surgical delivered year-on-year revenue growth of 23%, beating analysts’ expectations by 5.8%, and Neogen reported a revenue decline of 4.4%, topping estimates by 3.4%. Intuitive Surgical traded up 7.2% following the results while Neogen was down 8.9%.
Read our full analysis of Intuitive Surgical’s results here and Neogen’s results here.
There has been positive sentiment among investors in the healthcare equipment and supplies segment, with share prices up 10.8% on average over the last month. DexCom is down 3.4% during the same time and is heading into earnings with an average analyst price target of $86.88 (compared to the current share price of $59.78).
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.